NCT03655340 - A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 12, 2018

Primary Completion Date

March 16, 2022

Study Completion Date

March 16, 2022

Conditions

Haemophilia B

Interventions

DRUG

Alprolix

Extended half-life factor IX product

Trial Locations (18)

Swedish Orphan Biovitrum Research Site (CHU de Bordeaux), Bordeaux

Swedish Orphan Biovitrum Research Site, Brest

Swedish Orphan Biovitrum Research Site, Caen

Swedish Orphan Biovitrum Research Site, Chambéry

Swedish Orphan Biovitrum Research Site, Clermont-Ferrand

Swedish Orphan Biovitrum Research Site, Dijon

Swedish Orphan Biovitrum Research Site, La Réunion

Swedish Orphan Biovitrum Research Site, Lille

Swedish Orphan Biovitrum Research Site, Marseille

Swedish Orphan Biovitrum Research Site, Montpellier

Swedish Orphan Biovitrum Research Site, Nantes

Swedish Orphan Biovitrum Research Site, Nîmes

Swedish Orphan Biovitrum research site, Paris

Swedish Orphan Biovitrum research site, Poitiers

Swedish Orphan Biovitrum research site, Rennes

Swedish Orphan Biovitrum Research Site, Rouen

Swedish Orphan Biovitrum research site, Strasbourg

Swedish Orphan Biovitrum Research Site, Toulouse